While only 20% of the drugs on the market today are biologics, it is expected that with 650 biotechnology medicines in development in 2010 for more than 100 diseases, half the new drugs approved in 2015 will be biologics and most of them will be monoclonal antibodies.
By attending this conference you will:
Gain insight on various therapeutic targets on oncology, multiple sclerosis, cardiovascular and autoimmune disorders
Evaluate advances in antibody technology such as fragments, conjugates and multi-specific antibodies
Learn about future of monoclonal antibody technology
Hear about new antibody engineering and modification technologies
Examine platform approaches to monoclonal antibody purification
Find out new techniques in cell engineering for monoclonal antibody production
Explore antibody-based targeted therapy: taking advantage of the human innate immunity
Assess trends in capacity utilisation for therapeutic monoclonal antibody production
Improve antibody production using directed evolution
Investigate immunogenicity issues with drug development
Identify suitable assays for evaluating the immunogenicity of mAbs
Review contract production of mAbs for research and pre-clinical purposes
Understand navigation strategies for intellectual property in the antibody world
Review latest regulations, technologies, production methods and therapeutics
Be part of a major networking opportunity
Past Events
7th Annual Monoclonal Antibody Conference 2011 - 18-20 May 2011, London, United Kingdom (13431)
Annual Monoclonal Antibody Conference 2026
Important
Please, check "Annual Monoclonal Antibody Conference" official website for possible changes, before making any traveling arrangements
